Abstract
Immune checkpoint inhibitors (ICI) have revolutionized cancer care, but a minority of patients benefit, and responses may not be sustained. External beam radiotherapy (EBRT) can synergize with ICI to prompt remarkable tumor regression and even eradication. However, EBRT is poorly suited to widely disseminated disease. Targeted radiopharmaceutical therapy (TRT) uses a selective ligand to deliver radiation to cancer cells, and promising results achieved with this approach have led to regulatory approval of certain agents (ex. 177Lu-PSMA-617/Pluvicto™ for metastatic prostate cancer). To further improve therapeutic outcomes, combining TRT and ICI is a burgeoning research area, both preclinically and in clinical trials. Here we introduce basic TRT radiobiology and dosimetry as well as survey the emerging and clinically translated TRT agents that have been combined with ICI.
- Oncology: General
- Radiobiology/Dosimetry
- Radionuclide Therapy
- 177Lu-DOTATATE
- 177Lu-PSMA-617
- 223Ra
- Immune checkpoint
- Targeted radiopharmaceutical therapy
- Copyright © 2022 by the Society of Nuclear Medicine and Molecular Imaging, Inc.